Clinical Trial: NCT03022500
Pulmonary sarcomatoid_MEDI4736+Treme
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | Seoul National University Hospital |
| Information Provided By: | Seoul National University Hospital |
| Last Update Posted: | 2024-05-29 |
Study Overview
Brief Summary
To understand efficacy of Durvalumab(MEDI4736)+ Tremelimumab in Metastatic/relapsed pulmonary sarcomatoid carcinoma
Official Title
Phase II Study of Durvalumab + Tremelimumab in Pulmonary Sarcomatoid Carcinoma
Conditions
Durvalumab + Tremelimumab Combination Treatment, Pulmonary Sarcomatoid Carcinoma, NSCLC
Intervention / Treatment
- Drug: durvalumab + tremelimumab
Other Study ID Numbers
- PSC
Start Date (Actual)
2017-05-18
Primary Completion Date (Actual)
2018-02-28
Study Completion Date (Actual)
2019-11-30
Enrollment (Actual)
32
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Seoul National University Hospital |
| Information Provided By: | Seoul National University Hospital |
| Last Update Posted: | 2024-05-29 |
Study Overview
Brief Summary
To understand efficacy of Durvalumab(MEDI4736)+ Tremelimumab in Metastatic/relapsed pulmonary sarcomatoid carcinoma
Official Title
Phase II Study of Durvalumab + Tremelimumab in Pulmonary Sarcomatoid Carcinoma
Conditions
Durvalumab + Tremelimumab Combination Treatment, Pulmonary Sarcomatoid Carcinoma, NSCLC
Intervention / Treatment
- Drug: durvalumab + tremelimumab
Other Study ID Numbers
- PSC
Start Date (Actual)
2017-05-18
Primary Completion Date (Actual)
2018-02-28
Study Completion Date (Actual)
2019-11-30
Enrollment (Actual)
32
Study Type
Interventional
Phase
Phase 2